Therapy Area topics
Central Nervous System
Biohaven pops the Alzheimer’s bubble
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Lilly boosts biopharma with an early Alzheimer’s signal
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.
Diabetes
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Digital Health
Philips spends nearly $3bn to integrate Biotelemetry
The deal is a late entrant into 2020's top five mergers and acquisitions.
Prescription apps take off during lockdown
Digital therapeutics are going from strength to strength during the pandemic.
Can Omada do a Livongo?
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
Oncology
Merck KGaA’s dual immuno-oncology weapon misfires
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
Respiratory
Kinaset takes a sledgehammer to an asthma conundrum
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Source flop raises tezepelumab questions
Astrazeneca and Amgen hope the “totality of the data” will win out for their asthma project.
Various
Go or no go? New Year approval decisions for the US regulators
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
